Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Bones & muscles
Sermorelin
Also called GHRH(1-29), GRF 1-29
Sermorelin is a synthetic GHRH fragment once sold as Geref and now discontinued. See how it works, its FDA status, and what the research shows.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- October 13, 2025
- Last updated
- October 5, 2026
Key takeaway
Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH) that was once an approved medicine (Geref) for growth hormone testing and pediatric growth problems, later discontinued. Today it is supplied mainly as a compounded preparation to raise the body's own growth hormone, but there are no controlled trials establishing the marketed adult anti-aging or body-composition benefits. As of 2026 no approved sermorelin product is marketed, and it is banned in sport.
What is sermorelin?
Sermorelin is the shortest fully active fragment of human GHRH, the hypothalamic hormone that signals the pituitary to release growth hormone. Unlike most peptides in the wellness market, it has a prior approval history: It was marketed as Geref for assessing growth hormone secretion and for treating growth failure in children. That product was discontinued, and sermorelin is now supplied mainly as a compounded preparation and promoted for anti-aging and body composition in adults.
How does it work?
Sermorelin is a GHRH-receptor agonist. It binds the same pituitary receptor as natural GHRH and stimulates pulsatile growth hormone release, which in turn raises IGF-1. It is shorter-acting than CJC-1295 but works through the same pathway. The adult wellness claims rest on this growth-hormone-raising pharmacology rather than on demonstrated outcomes. This describes the proposed mechanism, separate from whether it produces the marketed results.
Is it FDA-approved?
Not currently. The table below sets out sermorelin's regulatory status.
| Area | Status |
| FDA approval | FDA-approved as Geref and then discontinued, reportedly for business reasons rather than a safety withdrawal; no FDA-approved sermorelin product is now on the market |
| Compounding | Available through compounding, and because it was a previously approved ingredient, its compounding footing differs somewhat from never-approved peptides, though its status remains under ongoing FDA review |
| Anti-aging and performance | Not approved for either use |
| Sport | GHRH analogs including sermorelin are prohibited at all times under the WADA list |
What does the research show?
The historical human data relate to its original approved uses, not the adult wellness market. Sermorelin's role in diagnosing growth hormone capacity and treating pediatric growth hormone deficiency was established, and physiology studies confirm that GHRH signaling augments nocturnal growth hormone release (here1). There are no controlled trials showing that sermorelin improves muscle, fat, recovery, or aging in healthy adults; those uses are extrapolated from its effect on hormone levels.
Sources: a GHRH physiology study (Jessup et al., European Journal of Endocrinology, 2004, DOI: 10.1530/eje.0.15105611), indexed on PubMed; FDA records on the discontinued Geref product; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.